Skip to main content

Table 1 Population characteristics

From: Relationship between cardiovascular risk and lipid testing in one health care system: a retrospective cohort study

 

Men

Women

Total, N (row%)

24,540 (41.2)

35,064 (58.8)

 

n (col%)

n (col%)

Age

 25–34

2,306 (9.4)

3,697 (10.5)

 35–44

5,290 (21.6)

7,242 (20.7)

 45–54

7,133 (29.1)

9,946 (28.4)

 55–64

6,700 (27.3)

9,063 (25.9)

 65–79

3,111 (12.7)

5,116 (14.6)

Cardiovascular riska

 Low (<10 %)

7,661 (38.9)

24,192 (77.1)

 Moderate (10–20 %)

6,290 (31.9)

5,378 (17.1)

 High (>20 %)

5,745 (29.2)

1,798 (5.7)

 Missing

4,844 [19.7]

3,696 [10.5]

 Diabetes

552 (2.3)

710 (2.0)

 BP-lowering medications, any fill in past year

4,870 (19.9)

6,477 (18.5)

Systolic blood pressure

 ≤140

18,265 (84.7)

28,956 (88.6)

 141–160

2,817 (13.1)

3,103 (9.5)

 161–180

438 (2.0)

537 (1.6)

 >180

56 (0.3)

91 (0.3)

 Missing

2,964 [12.1]

2,377 [6.8]

Total cholesterol

 <200

6,745 (46.5)

8,781 (41.0)

 200–239

5,508 (38.0)

8,352 (39.0)

 ≥240

2,256 (15.6)

4,273 (20.0)

 Missing

10,031 [40.9]

13,658 [39.0]

HDL cholesterol

 <40

2,534 (17.5)

770 (3.6)

 40–59

8,135 (56.1)

7,569 (35.4)

 ≥60

3,838 (26.5)

13,060 (61.0)

 Missing

10,033 [40.9]

13,665 [39.0]

LDL cholesterol

 <100

2,207 (20.7)

3,721 (24.1)

 100–129

3,945 (37.1)

5,808 (37.6)

 130–159

3,094 (29.1)

4,049 (26.2)

 160–189

1,101 (10.3)

1,467 (9.5)

 ≥190

302 (2.8)

401 (2.6)

 Missing

13,891 [56.6]

19,618 [56.0]

BMI

 <25

4,761 (22.8)

12,481 (38.2)

 25–29.9

9,220 (44.1)

9.646 (29.5)

 ≥30

6,913 (33.1)

10,545 (32.3)

 Missing

3,646 [14.9]

2,392 [6.8]

 Current smoker

2,188 (13.5)

3,130 (9.1)

 Missing

843 [3.4]

587 [1.7]

RUB

 0 = No diagnoses

2,687 (11.0)

2,097 (6.0)

 1 = Low

3,519 (14.3)

4,158 (11.9)

 2

4,697 (19.1)

5,248 (15.0)

 3

11,929 (48.6)

19,557 (55.8)

 4

1,355 (5.5)

3,450 (9.8)

 5 = High

353 (1.4)

554 (1.6)

Health plan

 Medicare

3,309 (13.5)

5,382 (15.4)

 Medicaid/Basic Health

315 (1.3)

673 (1.9)

 Commercial

19,945 (81.3)

27,699 (79.0)

 Private pay

971 (4.0)

1,310 (3.7)

Annual average primary care visits, past 5 years

 <1

8,257 (33.7)

6,572 (18.7)

 1 to <2

9,326 (38.0)

12,055 (34.4)

 2 to <3

4,130 (16.8)

8,255 (23.5)

 ≥3

2,827 (11.5)

8,182 (23.3)

Residence

 Rural

660 (2.7)

914 (2.6)

 Urban

23,880 (97.3)

34,150 (97.4)

Race

 White

14,866 (84.0)

25,805 (82.8)

 Asian

1,418 (8.0)

3,105 (10.0)

 Black

916 (5.2)

1,301 (4.2)

 Mixed race/Other

490 (2.8)

951 (3.1)

 Missing

6,850 [27.9]

3,902 [11.1]

Neighborhood-level variables

Median household income

 <$40,000

5,371 (21.9)

7,643 (21.9)

 $40,000 to <$60,000

11,394 (46.5)

16,410 (46.9)

 $60,000 to <$80,000

5,606 (22.9)

8,014 (22.9)

 ≥$80,000

2,114 (8.6)

2,913 (8.3)

 Missing

55 [0.2]

84 [0.2]

Education, % with some college

 <50 %

2,687 (11.0)

3,953 (11.3)

 50 % to <60 %

4,096 (16.7)

5,968 (17.1)

 60 % to <70 %

6,407 (26.2)

9,215 (26.3)

 70 % to <80 %

5,973 (24.4)

8,554 (24.5)

 ≥80 %

5,319 (21.7)

7,289 (20.8)

 Missing

58 [0.2]

85 [0.2]

  1. aCVD Risk score based on BMI-based risk calculations. When BMI-risk was missing, we used lab-based risk calculations (n = 698). The CVD risk equations are as follows:
  2. BMI-based CVD Risk Equations:
  3. Male, not treated with antihypertensive medications
  4. 100*(1-(0.88431^(exp([3.11296*ln(AGE) + 0.79277*ln(BMI) + 1.85508*ln(SBP) + 0.70953*SMOKE + 0.53160*DIAB] -23.9388))))
  5. Male, treated with antihypertensive medications
  6. 100*(1-(0.88431^(exp([3.11296* ln(AGE) + 0.79277* ln(BMI) + 1.92672* ln(SBP) + 0.70953* SMOKE + 0.53160* DIAB] -23.9388))))
  7. Female, not treated with antihypertensive medications
  8. 100*(1-(0.94833^(exp([2.72107* ln(AGE) + 0.51125* ln(BMI) + 2.81291* ln(SBP) + 0.61868* SMOKE + 0.77763* DIAB] -26.0145))))
  9. Female, treated with antihypertensive medications
  10. 100*(1-(0.94833^(exp([2.72107* ln(AGE) + 0.51125* ln(BMI) + 2.88267* ln(SBP) + 0.61868* SMOKE + 0.77763* DIAB] -26.0145))))
  11. Lab-based CVD Risk Equations:
  12. Male, not treated with antihypertensive medications
  13. 100*(1-(0.88936^(exp([3.06117*ln(AGE) + 1.12370*ln(TC)+−0.93263*ln(HDL) + 0.65451*SMOKE + 0.57367*DIAB + 1.93303* ln(SBP)]-23.9802))))
  14. Male, treated with antihypertensive medications
  15. 100*(1-(0.88936^(exp([3.06117*ln(AGE) + 1.12370*ln(TC)+−0.93263*ln(HDL) + 0.65451*SMOKE + 0.57367*DIAB + 1.99881* ln(SBP)]-23.9802))))
  16. Female, not treated with antihypertensive medications
  17. 100*(1-(0.95012^(exp([2.32888*ln(AGE) + 1.20904*ln(TC)+−0.70833*ln(HDL) + 0.52873*SMOKE + 0.69154*DIAB + 2.76157* ln(SBP)] -26.1931))))
  18. Female, treated with antihypertensive medications
  19. 100*(1-(0.95012^(exp([2.32888*ln(AGE) + 1.20904*ln(TC)+−0.70833*ln(HDL) + 0.52873*SMOKE + 0.69154*DIAB + 2.82263* ln(SBP)] -26.1931))))